Review article: acid-related disease--what are the unmet clinical needs? - Wikidata - wikimedia - TriplyDB

Review article: acid-related disease--what are the unmet clinical needs?

Review article: acid-related disease--what are the unmet clinical needs?

http://www.wikidata.org/entity/Q36478873

about

Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR.Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis Chemoprevention of esophageal adenocarcinoma Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan.Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.Dexlansoprazole MR.Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation.Acid peptic diseases: pharmacological approach to treatment.Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis.Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease.Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker.Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.

P2860

Q26741015-C595970B-4CF3-4BD8-A624-F4BDE20BA2E5 Q30278055-A78F5F51-4844-4672-8FE8-48B03B51AFC7 Q30431802-107E155A-E98A-42D6-BEF7-F14D8A9BB5BA Q34408890-26C17AC2-0B70-4362-BAC0-A1CD7D517CCF Q36281192-DDE0869A-3510-4063-AEEF-5147CA378BA9 Q37018462-71BFD872-B716-4A91-8B11-364ED12E7DFF Q37587228-D887D82E-E840-4DA1-89A7-F17B080C46A5 Q37696562-205AB939-3FA1-4795-A8A6-C106B7A95C77 Q37913063-9D35F059-8FB0-4CD1-B4C6-BF02AC9A51EB Q38025449-A7FEDDF2-2E96-4BC6-8FA0-F37D7C528C5D Q38825937-EAB12F41-8C71-4C91-A947-3CCF11EFBCCA Q38865456-F3972E10-EE06-4AF3-A4F6-C920AFCF6512 Q39746768-6A9360E6-7D8A-4F9B-BA2B-1FCDD9E4E3E2 Q41623112-68CDBEFF-D1C4-4C59-8F0C-5F8663AAF7C4 Q42923401-2218E858-7C6B-4A26-9681-6E90724A5F5B Q51642470-EC7E8C54-2BB8-488D-995C-2B74D8CA3605 Q55280841-583005E2-63F4-4A95-9EE2-5C9E83CBB498

P2860

Review article: acid-related disease--what are the unmet clinical needs?

http://www.wikidata.org/entity/Q36478873

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Review article: acid-related disease--what are the unmet clinical needs?

@ast

Review article: acid-related disease--what are the unmet clinical needs?

@en

type

label

Review article: acid-related disease--what are the unmet clinical needs?

@ast

Review article: acid-related disease--what are the unmet clinical needs?

@en

prefLabel

Review article: acid-related disease--what are the unmet clinical needs?

@ast

Review article: acid-related disease--what are the unmet clinical needs?

@en

P1433

Q36478873-D99FE3A6-CEFE-4EEA-B3E9-768E44415557

P1476

Q36478873-CB557DC1-473D-4EAF-B1D2-155E597AF077

P2093

Q36478873-86ABA3BA-66BF-44A8-858F-7442F6E05714

Q36478873-9CC6D488-DBD2-4FF4-A667-D8C8E8A94750

Q36478873-B8D9D39B-41E2-434B-93EA-A1FA09246692

P2860

Q36478873-05CEED3E-28DD-4B6B-9B6F-0745EB8FC883

Q36478873-0B11484A-842E-4D4E-9A10-775733A03E69

Q36478873-0F9571E2-5710-4B70-87C7-D133C7B821F3

Q36478873-13FB9645-264D-45B2-8A96-A22BA8F5AE62

Q36478873-18CB06D8-EE34-4B73-ACF2-E7AB5F64B4CE

Q36478873-19F80982-4766-4CFC-A96C-6EFD90821A8A

Q36478873-27F461EF-315E-4541-B890-A749157A67A7

Q36478873-28EDBE86-BA49-4798-97C0-65349F648437

Q36478873-31E3CC0F-9B27-4483-9E42-2C24F50BBBF3

Q36478873-3A2EFB52-D427-4909-A221-6F442517551B

P304

Q36478873-153CFC1A-0AD8-41D3-AD6A-8E28E96BA9AF

P31

Q36478873-51f6ffe8-637e-4ff8-b643-80dd0c9a941d

Q36478873-D32EF217-C9A0-4F05-9C92-2B0144B80972

P356

Q36478873-127C6F31-06E8-4E99-A427-2148F9C90D2F

P407

Q36478873-648228A9-F1DF-4CC7-A11E-2768289C312A

P478

Q36478873-8C3FC241-ABDC-4529-B42B-1383A3D620F9

P577

Q36478873-E50595AC-ABC6-471D-ACE6-A0C88EDCEC65

P5875

Q36478873-A560F371-FA07-4248-B3B7-B1E3EA8E51C7

P698

Q36478873-CFBD6DEA-6DCE-4042-9A53-0DEAA7D62307

P356

J.1365-2036.2006.02944.X

P1433

Alimentary Pharmacology & Therapeutics

P1476

Review article: acid-related disease--what are the unmet clinical needs?

@en

P2093

Barkun AN

http://www.w3.org/2001/XMLSchema#string

Katz PO

http://www.w3.org/2001/XMLSchema#string

Scheiman JM

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers

Gastroduodenal safety of cyclooxygenase-2 inhibitors

Gastrointestinal safety of selective COX-2 inhibitors

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

The Effect of Endoscopic Therapy in Patients Receiving Omeprazole for Bleeding Ulcers with Nonbleeding Visible Vessels or Adherent Clots

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.

Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy.

P304

9-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2036.2006.02944.X

http://www.w3.org/2001/XMLSchema#string

P407

P478

23 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7080436

http://www.w3.org/2001/XMLSchema#string

P698

16700899

http://www.w3.org/2001/XMLSchema#string